Advances in drug resistance and resistance mechanisms of four colorectal cancer-associated gut microbiota
- PMID: 40520636
- PMCID: PMC12164818
- DOI: 10.7717/peerj.19535
Advances in drug resistance and resistance mechanisms of four colorectal cancer-associated gut microbiota
Abstract
Colorectal cancer (CRC) is a common malignant tumor in the gastrointestinal tract with inconspicuous early symptoms, high morbidity and mortality, and poor prognosis. Gut microbiota are present in the human intestinal system and have certain functions, which include the integrity of the epithelial barrier and the enhancement of protective immune responses. The etiology of CRC is numerous and complex, including poor lifestyle and dietary habits, and instability of the gut microbiota, which is considered to be one of the major factors in the development of CRC, includes mainly Bacteroides fragilis, Fusobacterium nucleatum, Escherichia coli, and Enterococcus faecalis. Enrichment of these bacteria in CRC tumor tissues may increase other pro-inflammatory opportunistic pathogens and decrease butyrate-producing bacteria, leading to an imbalance in intestinal homeostasis (dysbiosis) and ultimately tumor formation. Antibiotic-induced changes in the gut microbiota affect tissue utilization and redox homeostasis of macronutrients and micronutrients. However, the long-term use and abuse of antibiotics has made the problem of drug resistance a difficult problem that currently plagues the regulation of gut microbiota, as well as a complicated issue in the prevention and treatment of CRC. In this review, we elucidated the drug resistance of four CRC-associated gut microbiota, namely Bacteroides fragilis, Fusobacterium nucleatum, Escherichia coli, and Enterococcus faecalis, and discussed the common and different aspects of the resistance mechanisms of the four gut microbiota, with the aim of providing a basis for the prevention and control of CRC.
Keywords: Bacteroides fragilis; Colorectal cancer; Drug resistance mechanism; Enterococcus faecalis; Enterotoxin-producing Escherichia coli; Fusobacterium nucleatum.
© 2025 Gan et al.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures





Similar articles
-
Gut microbiota, inflammatory bowel disease and colorectal cancer.World J Gastroenterol. 2022 Aug 14;28(30):4053-4060. doi: 10.3748/wjg.v28.i30.4053. World J Gastroenterol. 2022. PMID: 36157114 Free PMC article. Review.
-
[Gut microbiota: What impact on colorectal carcinogenesis and treatment?].Bull Cancer. 2018 Jan;105(1):70-80. doi: 10.1016/j.bulcan.2017.10.025. Epub 2017 Dec 6. Bull Cancer. 2018. PMID: 29217301 Review. French.
-
Global prevalence of Fusobacterium nucleatum and Bacteroides fragilis in patients with colorectal cancer: an overview of case reports/case series and meta-analysis of prevalence studies.BMC Gastroenterol. 2025 Feb 10;25(1):71. doi: 10.1186/s12876-025-03664-x. BMC Gastroenterol. 2025. PMID: 39930345 Free PMC article.
-
Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum.mBio. 2021 Apr 6;12(2):e00547-21. doi: 10.1128/mBio.00547-21. mBio. 2021. PMID: 33824205 Free PMC article.
-
Diet-mediated gut microbial community modulation and signature metabolites as potential biomarkers for early diagnosis, prognosis, prevention and stage-specific treatment of colorectal cancer.J Adv Res. 2023 Oct;52:45-57. doi: 10.1016/j.jare.2022.12.015. Epub 2022 Dec 31. J Adv Res. 2023. PMID: 36596411 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical